SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Cash from Operations data on file, last reported at 8800000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 2.98% year-over-year to 8800000.0 in Q1 2026; TTM through Mar 2026 was 28130000.0, a 16.56% increase from a year earlier, with the FY2025 full-year figure at 28400000.0, up 19.78% from the prior year.
• Cash from Operations for Q1 2026 stood at 8800000.0, down from 4932000.0 in the prior quarter.
• Over the last five years, Cash from Operations for SLS reached as high as 4825000.0 in Q4 2023 and fell as low as 12127000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 7518882.35 across 5 years, with a median of 7153000.0 in 2024.
• Across the five-year window, Cash from Operations slumped 69.61% in 2023 and jumped 31.05% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 5152000.0 in 2022, then increased by 6.35% to 4825000.0 in 2023, then sank by 48.25% to 7153000.0 in 2024, then soared by 31.05% to 4932000.0 in 2025, then tumbled by 78.43% to 8800000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 8800000.0 in Q1 2026, 4932000.0 in Q4 2025, and 7068000.0 in Q3 2025.